Related Experiment Video
Updated: Jul 10, 2026
04:27
Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation
1Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. lbashoura@mdanderson.org
Bone Marrow Transplantation
|October 16, 2007
Summary
High-dose inhaled corticosteroids may effectively treat post-transplantation constrictive bronchiolitis (PTCB), a common complication after allogeneic hematopoietic stem cell transplantation (HSCT). This treatment stabilized lung function in patients with PTCB.
Area of Science:
- Pulmonology
- Hematology
- Immunology
Background:
- Post-transplantation constrictive bronchiolitis (PTCB) is a frequent pulmonary complication in allogeneic hematopoietic stem cell transplantation (HSCT) survivors.
- PTCB is a late manifestation of graft-versus-host disease (GVHD) and its current treatment with systemic corticosteroids has significant side effects.
- Topical corticosteroids are used for other GVHD manifestations to mitigate systemic side effects.
Purpose of the Study:
- To evaluate the efficacy of high-dose inhaled corticosteroids for treating PTCB.
- To assess the impact of inhaled corticosteroids on airflow obstruction in PTCB patients.
Main Methods:
- Retrospective analysis of adult patients diagnosed with new-onset PTCB.
- Patients received high-dose inhaled fluticasone propionate (500-940 mcg BID).
- Forced expiratory volume in 1 second (FEV1) was monitored before and after treatment.
Main Results:
- Seventeen patients with PTCB showed a significant decline in FEV1 post-HSCT (median 53%).
- Treatment with inhaled corticosteroids led to improvement in airway obstruction symptoms.
- FEV1 stabilized in patients 3-6 months after initiating inhaled corticosteroid therapy.
Conclusions:
- High-dose inhaled corticosteroids demonstrate potential efficacy in treating PTCB.
- Inhaled corticosteroids may offer a localized treatment option with potentially fewer side effects than systemic regimens.
- Further prospective studies are warranted to confirm the efficacy of inhaled corticosteroids for PTCB.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation